Science ❯ Biotechnology

Drug Development

Clinical Trials Clinical Research Therapeutics Oncology Cancer Research Regulatory Affairs Cancer Treatments Formulation Science Research and Development Targeted Therapies Cancer Therapies Antibody Therapies Peptide Synthesis Therapeutic Candidates Phase 2 Studies Smart Insulin Non-Pharmaceutical Interventions Therapeutic Innovations Biomacromolecules Artificial Intelligence Integrated Stress Response Manufacturing Lifespan Extension Autoimmune Conditions ANAVEX®2-73 Mechanism of Action Innovative Therapies Clinical Studies Anti-Cancer Drugs Biosimilars Preclinical Research Analytical Techniques Nanoparticle Formulation Preclinical Testing Nanotechnology FDA RNA Interference Regulatory Approval Market Trends Therapeutic Interventions Investigational Drugs Innovation Clinical Production Veterinary Medicine Cytoskeletal Biology Antiviral Agents Endocannabinoid System Immunohistochemistry Rare Diseases Aesthetic Applications Chronic Diseases Metabolic Disorders Antibody-Drug Conjugates FDA Regulations Advanced Therapies Amino Acids Protein Structure Prediction Market Access Preclinical Trials AI in Drug Discovery Highly potent molecules

Kodiak Drugs Clear Phase 3 for Wet AMD and Shares Soar

The company said it will seek U.S. approval by filing a Biologics License Application for Zenkuda in Q4 to pursue its first commercial product.

Stanford’s 37,000‑Agent 'Virtual Biotech' Finds Trial‑Success Signal and Designs Lung‑Cancer Therapy

BioMarin and Ascendis Reach Global Patent Settlement Over Yuviwel

Amylyx’s Avexitide Cuts Moderate‑to‑Severe Post‑Bariatric Hypoglycemia Events 55% in Phase 3

Fulcrum Agrees to Merge With Slate Medicines, Plans Nasdaq Relaunch as SLTE

Samsung Biologics Launches $1.8 Billion Bid for Swiss Peptide CDMO PolyPeptide

Takeda Signs $600 Million‑Value AI Drug Discovery Deal With Insilico

Akari’s AKTX-101 Shows Preclinical Synergy With KRAS Inhibitor as Stock Soars

FDA Accepts ImmunityBio Filing to Expand ANKTIVA Use in Bladder Cancer

Altimmune Targets Second-Half 2026 Launch for Global Phase 3 MASH Trial

UCB to Buy Candid Therapeutics for Up to $2.2 Billion

Erasca Shares Plunge After Trial Death and Patent Challenge

Sagimet Prices $175 Million Stock Offering as It Plans U.S. Phase 3 Acne Trial

Trump Order to Speed Psychedelic Therapies Sends Compass Pathways to 52-Week High

Kailera Leaps 62% in Nasdaq Debut After $625 Million IPO

Traws Pharma Raises $10 Million in PIPE With Up to $60 Million Tied to Trial Milestones

RTW Buys $116 Million of Cogent Biosciences as Kynam Trims $48 Million Stake

Viking Therapeutics Pushes VK2735 Through Pivotal Trials as Next Enrollment Milestone Nears

EU Grants Conditional Approval for ImmunityBio’s Anktiva in BCG‑Unresponsive Bladder Cancer

AstraZeneca Pledges $15 Billion China Expansion Through 2030